ACRS · NASDAQ
Aclaris Therapeutics, Inc.
$3.55 -0.24 (-6.33%)
Company overview
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company that develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment identifies and develops innovative therapies to address significant unmet needs in immuno-inflammatory diseases. The Contract Research segment provides laboratory services. The company develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and psoriatic arthritis and hidradenitis suppurativa, and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $523M
- Employees
- 61
- Headquarters
- Wayne, PA
- Website
- aclaristx.com
- CEO
- Neal S. Walker
- Listed
- October 6, 2015
- P/E
- -6.57
- Dividend yield
- 0.00%
Company financials
- Revenue
- $8.4M
- Gross profit
- $6.4M
- Operating income
- -$80.5M
- EBITDA
- -$73.1M
- Net income
- -$69.7M
- EPS
- -$0.56
- Total assets
- $199M
- Total debt
- $2M
- Gross margin
- 76.34%
- Net margin
- -832.58%
- Earnings yield
- -15.22%
No geographic segmentation.
Showing FY 2025
ACRS
1D
NASDAQ
O3.79H3.85L3.73C3.79+0.04 (+1.07%)Vol429.42K